Skip to main content
OpenTrials
Completed

NCT Number: NCT03371615

Evaluation of the Tolerance and Safety of a New Partly Fermented Anti-regurgitation Infant Formula

A randomised, controlled, double-blind trial to evaluate the tolerance and safety of a new partly fermented anti-regurgitation infant formula containing prebiotics and locust bean gum in infants with regurgitation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 week–13 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Poliklinika Ginekologiczno-Poloznicza Sp. Z.O.O Sp.K, Bialystok, Poland

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Singleton healthy term infant aged 3 - 13 weeks;
  • Gestational age at birth 37- 42 weeks;
  • Normal birth weight for gestational age and gender i.e. 10th to 90th percentile compared to the WHO or local growth charts;
  • Infants with regurgitation that are otherwise healthy, based upon the following criteria: 1) Regurgitation of 2 or more times per day for 1 or more weeks according to reported history, 2) an indication for the use of AR formula according to the investigator at screening/randomisation.
  • Fully formula fed for at least 7 days before screening/randomisation;
  • Written informed consent from the parent(s) and/or legally acceptable representative(s), aged ≥ 18 years.

-

Exclusion criteria

  • 1. History of retching, hematemesis, aspiration, apnoea, failure to thrive, feeding or swallowing difficulties or abnormal posturing; 2. Gastrointestinal infection within 4 weeks prior to randomisation; 3. Congenital condition and/or previous or current illness and (or) medication use that could interfere with the main study outcomes according to the investigator; 4. Known cow's milk protein allergy, lactose intolerance, or galactosaemia including history of any other allergic manifestations or known allergy to any of the study product ingredients (especially scGOS); 5. Presence of any other gastrointestinal symptom(s)/disorder(s) that are not functional in nature, as assessed by the investigator's clinical judgement; 6. Received any of the following products/medication prior to randomisation: systemic antibiotics, prokinetics, proton pump inhibitors, complementary feeding/weaning within 4 weeks prior to randomisation; 7. Incapability of the parent(s) to comply with the study protocol or investigator's uncertainty about the willingness or ability of the parent(s) to comply with the protocol requirements; 8. Current participation in another clinical intervention study.

Treatment and study plan

Anti-regurgitation infant formula

Other

Anti regurgitation infant formula

Primary outcomes

  1. GI tolerance

    Time frame: 4 weeks

    To assess the gastrointestinal (GI) tolerance of the investigational product compared to the control product based on Infant Gastrointestinal Symptom Questionnaire(IGSQ) symptoms score containg 13 questions on a 7 point scale

Sponsors and collaborators

Lead sponsor

Nutricia Research

Industry

Registry information

Official study title

A Randomised, Controlled, Double Blind Trial to Evaluate the Tolerance and Safety of a New Partly Fermented Anti-regurgitation Infant Formula Containing Prebiotics and Locust Bean Gum in Infants With Regurgitation.

Acronym: Leopard

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Dec 13, 2017
Registry last updated
Dec 30, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.